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Intercellular differences of chromosomal content in the same individual are defined as
chromosomal mosaicism (alias intercellular or somatic genomic variations or, in a number of
publications, mosaic aneuploidy). It has long been suggested that this phenomenon poorly
contributes both to intercellular (interindividual) diversity and to human disease. However, our
views have recently become to change due to a series of communications demonstrated a higher
incidence of chromosomal mosaicism in diseased individuals (major psychiatric disorders and
autoimmune diseases) as well as depicted chromosomal mosaicism contribution to genetic
diversity, the central nervous system development, and aging. The later has been produced by
significant achievements in the field of molecular cytogenetics. Recently, Molecular Cytogenetics has
published an article by Maj Hulten and colleagues that has provided evidences for chromosomal
mosaicism to underlie formation of germline aneuploidy in human female gametes using trisomy 21
(Down syndrome) as a model. Since meiotic aneuploidy is suggested to be the leading genetic cause
of human prenatal mortality and postnatal morbidity, these data together with previous findings
define chromosomal mosaicism not as a casual finding during cytogenetic analyses but as a more
significant biological phenomenon than previously recognized. Finally, the significance of
chromosomal mosaicism can be drawn from the fact, that this phenomenon is involved in genetic
diversity, normal and abnormal prenatal development, human diseases, aging, and meiotic
aneuploidy, the intrinsic cause of which remains, as yet, unknown.
Chromosomal mosaicism was originally defined as the
presence of cells differing with respect to their chromo-
some complement in the same individual [1]. Although
chromosomal mosaicism is repeatedly registered during
cytogenetic analysis, one of the commonest genetic tests
in medical genetics [2], its significance remains usually
underappreciated. Nonetheless, during the last decade, a
growing amount of studies has demonstrated that chro-
mosomal mosaicism does contribute to human diversity
[3-7], diseases [2,4,5,7-12], early prenatal brain develop-
ment [3,13], and aging [14]. However, the real biomedical
meaning of chromosomal mosaicism in humans is hardly
known.
One of the previous studies published in Molecular Cytoge-
netics  [15] has brought evidences that chromosomal
mosaicism plays a role in the generation of meiotic aneu-
ploidy known to be the leading genetic cause of human
prenatal death and congenital malformations/learning
disabilities [4,5,16]. Studying chromosome 21 in ovarian
cells of normal female foetuses, Prof. Maj Hulten and her
colleagues were able to give experimental support for their
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original hypothesis suggesting meiotic aneuploidy in
human conceptuses to be the result of ovarian germline
mosaicism that is produced during the normal prenatal
development [15]. The data fit well with current concepts
in biology of aneuploidy, essentially drawn from studies
of trisomy 21 (Down's syndrome) [16]. More specifically,
these findings have the potential to explain maternal age
effect, recurrence of aneuploidy at subsequent concep-
tions, and abnormal maternal recombination patterns
previously found via linkage analyses [15]. Although the
idea put forward in this article has revolutionized our
thinking about maternal meiotic aneuploidy suggesting
mitotic aneuploidy to lie at the origin of meiotic aneu-
ploidy, there was a strong experimental background for
this hypothesis. Firstly, it has been recently noticed that
chromosomal mosaicism is frequent among human foe-
tuses, achieving the rate of 25% in spontaneous abortions
[17]. Additionally, the confinement of chromosomal
mosaicism to the specific tissue is a known phenomenon.
As early as 1983, Kalousek and Dill have described the
existence of chromosomal mosaicism exclusively con-
fined to the placenta (confined placental mosaicism)
[18]. About a year ago, there have been shown that
somatic chromosomal mosaicism confines to the devel-
oping human brain in a significant proportion of normal
human conceptions. Furthermore, it has been established
that increase of mosaic aneuploidy in the developing
human brain is an integral component of the human pre-
natal central nervous system development [13].
Therefore, one can conclude: (i) chromosomal mosaicism
is extremely frequent in human foetuses; (ii) chromo-
somal mosaicism confines as to extraembryonic tissues
(placenta) as to embryonic tissues (central nervous system
and ovarian tissue). It is reasonable to suspect, that the
later could be one of the major source for human tissue-
specific pathology or multi-system diseases (including
those that arise due to meiotic errors), as exemplified by
M. Hulten and colleagues [15] as well as previous publica-
tions [4,5,7-12,17]. To understand whether chromosomal
mosaicism has the potential to mediate intercellular
diversity (somatic genome variations in unaffected indi-
viduals), one should address studies performed to reveal
the real rate of cell-to-cell chromosomal number variabil-
ity in unaffected human tissues [3-6,13-15,18-24] (Table
1). It is to note that almost all tissues, if thoroughly ana-
lyzed by a molecular cytogenetic technique, exhibit aneu-
ploid cells. Thus, we can highlight the major difficulty for
studies targeted at revealing effects of chromosomal
mosaicism referred to the definition of non-pathogenic
level of aneuploidy in a tissue. Therefore, an association
between chromosomal mosaicism and an alteration to
cellular/tissular physiology requires thorough control
study of unaffected individuals (tissues).
Focusing on diseases associated with chromosomal mosa-
icism, one can note the broad spectrum of pathology asso-
ciated with this type of somatic genomic variations from
cases of chromosomal syndromes to complex neuropsy-
chiatric and immune diseases [2-13,19]. Prof. Hulten and
Table 1: Chromosomal mosaicism in presumably normal human tissues.
Tissue Description References
Ovarian tissues Small, but significant proportion of aneuploid cells (trisomy 21) in ovarian tissues of normal female fetuses [15]
15–20% of human oocytes [19]
Sperm 2–10% of spermatozoa (0.1–0.2% per chromosome) [20]
Chorionic villi approaching 24% (~1% of aneuploid cells per chromosome) [13]
Fetal human brain approaching 30% (~1.5 of aneuploid cells per chromosome) 35% including chromosomal mosaicism confined to 
the fetal brain
[3,13]
Placenta No generalized data; chromosomal mosaicism observed in ~2% of foetuses (9–11 weeks of gestation) referred to 
prenatal diagnosis
[21]
Skin (adults) 2,2% and 4,4% (in young and old individuals, respectively) [22]
Liver (adults) ~3% [23]
Blood (adults) 1–2% (randomly selected autosomes) and 3% (chromosome X) [24]
Adult human brain 0.1–0.7% (autosomes and chromosome Y), 2% (chromosome X); tending to approach 10%, in total [3,4,6]Molecular Cytogenetics 2008, 1:26 http://www.molecularcytogenetics.org/content/1/1/26
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colleagues [15] have added meiotically originated aneu-
ploidy syndromes to the "chromosomal mosaicism dis-
ease list". Furthermore, it suggests the commonest genetic
cause of prenatal deaths to arise from chromosomal
mosaicism, as well. Table 2 overviews current knowledge
about chromosomal mosaicism contribution to human
prenatal mortality and postnatal morbidity. We may con-
clude that the confinement of chromosomal mosaicism is
likely to be the reason of tissue-specific dysfunction as
exemplified by brain diseases and fetal brain and ovarian
tissues [4,5,7,8,12,13,15]. Consequently, attempts to
identify the role of chromosomal mosaicism in human
pathology should directly evaluate malfunction tissue.
Unfortunately, due to limited availability of the majority
of human tissues for extended genetic studies and com-
plexity of molecular cytogenetic analyses of low-level ane-
uploidy, such evaluations are rare. To date, only neural
and ovarian tissues were assessed by high-resolution
molecular cytogenetic techniques [3,6,8,12,13,15,25].
Nevertheless, tissues (cell types) more frequently used for
cytogenetic studies (blood lymphocytes, skin fibroblasts,
chorionic villi etc.) can also provide for supporting
hypotheses suggesting chromosomal mosaicism to be a
possible genetic mechanism underlying different human
diseases [4,5,7,10,11,14,17,18,25,26]. Moreover, related
studies have shed light on the understanding of the nature
of some monogenic diseases that are observed in males
despite the lethality (i.e. Rett syndrome) [27]. Regardless
these achievements chromosomal mosaicism is still
poorly described phenomenon. The latter is acknowl-
edged to be related to technical problems encountered
during attempts to detect chromosomal mosaicism [4,5].
Addressing the technical side of molecular cytogenetic
analysis of somatic genome variations, one can come to
the rueful conclusion that current achievements in the
field are exiguously appreciated leading, thereby, to slow-
ing down the somatic genome variation research. Looking
at recent advances in interphase cytogenetics, it is to note
that powerful methodological basis for high-resolution
surveys of chromosomal mosaicism does exist [28]. Fortu-
nately, examples of such studies are present in the availa-
ble literature [6,11-13,15,17,28]. In this context, it is to
mention the development of a molecular cytogenetic
technique (interphase chromosome-specific multicolor
banding) providing for visualization of the whole inter-
phase chromosome in a cell [6,13,29], exemplified by Fig-
ure 1. Thus, researchers of somatic genome variation have
to pay attention to these molecular cytogenetic develop-
ments.
Since chromosomal mosaicism is more likely to manifest
as aneuploidy, it appears important to delineate the way
aneuploidy occurs during the ontogeny or "aneuploidza-
tion pathway" (Figure 2). Current data suggest aneu-
ploidization to represent a process that accompanies
Aneuploidy in the fetal human brain Figure 1
Aneuploidy in the fetal human brain. Interphase chromo-
some-specific multicolor banding (ICS-MCB) allowing bar-
coding painting of the whole chromosome 9 in its integrity; 
from left to right: monosomy, disomy (normal chromosomal 
complement) and trisomy (partially reproduced from Yurov 
et al. [13], an open-access article distributed under the terms 
of the Creative Commons Attribution License).Molecular Cytogenetics 2008, 1:26 http://www.molecularcytogenetics.org/content/1/1/26
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human development. Being a devastative condition, ane-
uploidy causes prenatal death and/or chromosomal syn-
dromes associated with severe developmental delays
hardly compatible with life [4]. The human central nerv-
ous system development depicts that aneuploidy should
be cleared, unless a pathogenic condition is produced
[13]. Therefore, an "antianeuploidization" process (see
legend to Figure 2) does exist in human, which is required
for a human conception to develop into a newborn and,
subsequently, to develop through the postnatal period of
life. However, "antianeuploidization" seems to slowdown
during human aging probably associated with aging or
tumorigenesis. The latter is supported by current concepts
in cancer and aging research [14,30]. The aneuploidiza-
tion pathway seems, therefore, to be a kind of universal
cascade of processes that leads to human disease, depend-
ing on the performance of the opposition processes,
which we have arbitrarily called "antianeuploidization".
Contrariwise, a balance between aneuploidization and
"antianeuploidization" provides human organism to
develop normally unless the "antianeuploidzation" will
slow down (Figure 2). We suggest that aneuploidization
of a tissue should be the key process to produce the dys-
function. Being confined to the specific cell population, it
probably causes tumorigenesis, whereas the whole tissue
affected by aneuploidy should degenerate. This is partially
supported by the data on brain diseases [4,12,25]. Not-
withstanding, such attracting hypotheses concerning ane-
uploidization, that assume chromosomal mosaicism to
be associated with human diseases, are to be tested.
The report that has inspired this communication
addresses basic side of chromosome mosaicism research.
However, Molecular Cytogenetics has published a series of
original researches, which have paid attention to practical
side of chromosomal mosaicism [31-36]. These have
demonstrated that chromosomal mosaicism is an appre-
ciable phenomenon frequently encountered in small
supernumerary marker chromosomes (sSMC) research
[31-33,35]. Furthermore, it provided evidences that
mosaic structural chromosome rearrangements are likely
to occur more frequently, than previously recognized
[4,5,34,36]. In the light of studying sSMC, it should be
additionally mentioned that chromosomal mosaicism
could be cryptic [37,38] and dynamic [39]. The former is
referred to as occurrence of more complex mosaics than
revealed after karyotyping [37]. The latter is the occur-
rence of new genetic imbalances from an already abnor-
mal cell or mosaicism resulting from behavioral
peculiarities of a rearranged chromosome [39]. These two
Table 2: The load of chromosomal mosaicism to human prenatal mortality and postnatal morbidity
Condition/disease Description References
Spontaneous abortions ~25% of all spontaneous abortions (~50% of 
spontaneous abortions with chromosome 
abnormalities) exhibit chromosomal mosaicism
[17]
Chromosomal syndromes 3–18% (depending on chromosome) [4,5,7]
Mental retardation and/or multiple congenital 
malformation
~3.5% in institutionalized children Vorsanova & Yurov, unpublished observations
Autism 16% in children with autism 
(~10% X chromosome aneuploidy in male 
children)
[11]
Schizophrenia Mosaic aneuploidy of chromosomes 1, 18 and X 
in cells of the schizophrenia brain; mosaic X 
chromosome aneuploidy in blood lymphocytes
[7,8,12]
Autoimmune diseases Monosomy of chromosome X in systemic 
sclerosis (6.2% of cells) and autoimmune thyroid 
disease (4.3% of cells)
[10]
Alzheimer disease over 10% in brain cells; increase of aneuploidy of 
chromosome 21 in mitotic cells 
(skin fibroblasts or blood lymphocytes)
[25,26]
Meiotic aneuploidy Chromosomal mosaicism confined to fetal 
ovarian tissues has potential to result into 
meiotic aneuploidy in conceptions
[15]Molecular Cytogenetics 2008, 1:26 http://www.molecularcytogenetics.org/content/1/1/26
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types of chromosomal mosaicism require the application
of high-resolution molecular cytogenetic techniques, i.e.
subcenM-FISH or multicolor banding (MCB) [37-39].
This takes us back to the technical side of chromosome
mosaicism detection and forces to conclude again that
studying chromosomal mosaicism without taking into
account new molecular cytogenetic techniques is almost
useless. Here, it is to mention high-resolution genome
screening approaches based on array-CGH. Such molecu-
lar cytogenetic techniques are extremely powerful for
delineation of chromosomal breakpoints, identification
of new microdeletion syndromes, and uncovering
genomic variations in health and disease [7]. Related pos-
sibilities have made array-CGH-based techniques almost
the most popular ones in current medical genetics. How-
ever, related approaches are poorly inapplicable (or even
completely inapplicable) for uncovering low-level, cryptic
and dynamic mosaicism. Therefore, genome screens by
array-CGH miss cases of chromosomal mosaicism. This
point should to be considered by researchers who plan to
study this type of intercellular (somatic) genomic varia-
tions, as well.
Finishing our overview of chromosomal mosaicism in the
light of the latest biomedical achievements, it is to high-
light several points: (i) intercellular variations manifest-
Current concepts in biology of chromosomal mosaicism: somatic-germline aneuploidization pathway Figure 2
Current concepts in biology of chromosomal mosaicism: somatic-germline aneuploidization pathway. Normal prenatal and 
postnatal development is hypothesized to be a matter of balance between two progressive processes: aneuploidization and 
"antianeuploidization" (the latter is arbitrarily covered by such term because it is still not completely clear what processes 
underlie the clearance of aneuploid cells in humans). Germline aneuploidzation results into prenatal death of aneuploid 
embryos or into chromosomal syndromes in newborns. Aneuploidization is observed in fetal germline tissues and in the fetal 
brain. This, if not cleared, has the potential to produce tissue-specific chromosomal mosaicism that can underlie the pathogen-
esis of brain diseases either in childhood or in adulthood. It also can be the reason of germline aneuploidization (mentioned 
earlier). Aneuploidization in adulthood (in some cases, in childhood) is suggested to be a key process of tumorigenesis and 
aging. This probably originates from the age-/environment-dependant inhibition of "antianeuploidization" processes.Molecular Cytogenetics 2008, 1:26 http://www.molecularcytogenetics.org/content/1/1/26
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ing as chromosomal mosiacism are likely to be involved
in the genetic diversity; (ii) significant proportion of
human pathogenic conditions are associated with chro-
mosomal mosaicism; (iii) chromosomal mosaicism is
still underappreciated biomedical phenomenon that
requires additional evaluations ; (iv) current molecular
cytogenetics possesses sufficiently powerful tools for
uncovering the role of chromosomal mosaicism.
Together, it suggests future biomedical research to involve
studies of chromosomal mosaicism, which have the
potential to give us new insights into pathobiology of
human diseases and to help our understanding of the
intercellular genomic variations.
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